Fulcrum repurpose drug for FSHD

Published Date
Beatriz Bustillo Ramirez
Orange box stating: Breaking news research

Update July 2019: Fulcrum Therapeutics has launched two Phase 2 clinical trials testing losmapimod in adults with FSHD. The studies will take place in the Netherlands, US and Canada. More information is available on clinicaltrials.gov.

Fulcrum Therapeutics has obtained rights to losmapimod from GlaxoSmithKline (GSK). This drug has been tested in 24 clinical trials for multiple indications, including heart and lung disease, so it is known to be generally safe. Fulcrum is interested in losmapimod because it has found that the drug can switch off DUX4 in cells originating from people with facioscapulohumeral muscular dystrophy (FSHD). The company plans to initiate phase 2 trials testing losmapimod in people with FSHD in mid 2019.

Further information

Read Fulcrum’s press release on losmapimod.

Find out more about taking part in clinical trials.

If you have any questions about this news story or any other FSHD research, please contact the MDUK Research Line on 020 7803 4813 or email research@musculardystrophyuk.org.

Keep in touch